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Background: Clinical trials in cystic fibrosis (CF) currently use laboratory-specific reference ranges to evaluate chemistry and hematology
measurements. Laboratory-specific normal reference ranges may not accurately reflect what is abnormal but clinically insignificant among
CF patients.
Methods: To address this concern, data from the Phase III trial of inhaled tobramycin in CF patients was used to describe the distribution and
variability of laboratory parameters. The laboratory specimens were analyzed at a central laboratory after being obtained at baseline and
throughout the 24-week trial.
Results: At the time of entry into the clinical trial, 91% (463 of 508) of patients had at least a single value outside the normal range. Liver
function tests (AST, ALT) were above the normal range in 16% and 12% of the patients respectively, with 2.4% of patients having an
AST>2.0 times the upper limit of normal. Of the 243 patients on placebo, 242 (99.6%) had at least one laboratory parameter that changed
from normal to abnormal during the 24-week follow-up period. Of those same placebo patients, 11.5% (N=28) had a laboratory parameter
change from a Common Toxicity Criteria (CTC) grade 0 to grade 2 or higher during follow-up.
Conclusions: Patients with CF frequently have laboratory values outside the normal range and have significant longitudinal variability of
laboratory values. Interpretation of adverse events in the clinical trial setting may be complicated by the underlying high rates of some
laboratory abnormalities in the CF population.
This data was presented in poster format at the American Thoracic Society International Conference, Atlanta, USA, 2002, appearing
subsequently in the Conference proceedings [Goss CH, Mayer-Hamblett N, Yunker A, Waltz DA, Kronmal RA, Ramsey BW. Laboratory
parameter profiles among patients with cystic fibrosis. Am J Rep Crit Care Med 2002;165(8):A283].
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Cystic fibrosis (CF) is one of the most common inherited
fatal diseases in Caucasians with a reported incidence of CF
from 1 in 2000 to 1 in 3200 live births [1]. Over the past thirty
years, the median age of survival has improved from 14 years⁎ Corresponding author. University of Washington Medical Center,
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doi:10.1016/j.jcf.2006.05.012in 1969 to 35 years in 2004 in the United States [2]. Clinical
trials in CF currently use laboratory-specific reference ranges
that are based on a non-CF population to identify chemistry
and hematology abnormalities. These abnormalities are used
to both determine eligibility prior to entry into a trial and
monitor safety during a trial. The laboratory measurements
are compared to a reference or normal range, whereby
measurements that are outside the limits of the range are
classified as laboratory abnormalities. It is unknown whether
the laboratory-specific reference ranges need to be specifi-
cally tailored to reflect the physiology of CF patients as theed by Elsevier B.V. All rights reserved.
Table 1
Clinical characteristics of all study subjects compared to just those subjects
who received placebo
Clinical characteristic All patients Placebo patients
N 520 262
Male sex—no. (%) 281 (54) 132 (50)
Age 116 (22) 61 (23)
6–12 years—no. (%) 130 (25) 67 (26)
13–17 years—no. (%) 274 (53) 134 (51)
≥18 years—no. (%) 20.7 (9.8) 20.6 (10.0)
Mean (±SD) 50.6 (16.2) 51.2 (16.8)
Number of patients with
available data (%)
504 (97%) 243 (93%)
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abnormal but clinically insignificant among CF patients.
This issue is of particular importance when evaluating
laboratory parameters for safety using Common Toxicity
Criteria (http://ctep.cancer.gov/reporting/ctcnew.html) [3,4]
in early phase clinical trials with a very small or no placebo
group. No literature to date has clearly described baseline
laboratory parameters in CF patients participating in clinical
trials and how they compare to laboratory-specific reference
ranges developed using a healthy population. Additionally,
there is no data in the literature which describes the intra-
individual biologic variation among CF patients participating
in clinical trials and only limited data regarding this variation
in clinical practice. To address this concern, cross-sectional
and longitudinal analyses were performed using data from a
large CF clinical trial to summarize chemistry and hematol-
ogy measurements in relation to laboratory-specific reference
ranges. Some of the results of these studies have been
previously reported in the form of an abstract [5].
2. Methods
2.1. Description of data
Data from the Phase III trial of TOBI® (inhaled
tobramycin) in CF patients were used to describe distribu-
tions of laboratory parameters that were obtained at baseline
and throughout the clinical trial [6]. The study included two
multicenter, double-blind, placebo-controlled trials of inter-
mittent administration of inhaled tobramycin in patients with
cystic fibrosis with Pseudomonas aeruginosa infection. The
study enrolled patients in the United States from 69 different
medical centers from August 1995 to October 1996. To be
enrolled in the study, patients had to have a respiratory tract
culture yielding P. aeruginosa, be at least 6 years of age, have
a forced expiratory volume in the first second (FEV1)>25%
and <75% of the predicted value, absence of B. cepacia in
respiratory cultures in the prior 2 years, and uncompromised
renal function (creatinine<2 mg/dl [177 mmol/l]). A total of
520 patients were randomly assigned to receive three cycles
of either 300 mg of inhaled tobramycin or placebo (5 ml of
one-quarter strength normal saline with 1.25 mg of quinine
sulfate added); each cycle consisted of twice-daily adminis-
tration of study drug for 4 weeks, followed by 4 weeks with
no study drug. The duration of the study was 24 weeks and
key efficacy end points included pulmonary function, the
density of P. aeruginosa in sputum, and hospitalization rates.
Safety was monitored via adverse events and laboratory
measurements obtained from serum and processed at a
centralized laboratory. Laboratory measurements were avail-
able at baseline and at weeks 2, 4, 6, 8, 12, 16, 20 and 24. To
assess these measurements in the absence of study drug, the
laboratory data evaluated in our study included all available
baseline data and longitudinal data from only the placebo
patients. The analysis of anonymous data from the inhaled
tobramycin trial was approved by the Institutional ReviewBoard at University of Washington Medical Center, Seattle,
WA. This analysis and manuscript was also approved by
the CF Therapeutics Development Network publication
committee.
2.2. Design and procedures
Abnormalities in laboratory parameters were defined
using the age and gender-specific laboratory-defined normal
ranges used by the centralized laboratory in the inhaled
tobramycin randomized controlled trial. The normal ranges
were derived from a normal healthy population and revised
every 2 years. The upper and lower limit of normal used in
this study represent the 95% confidence intervals derived
from this normal population. Gradation of severity of the
abnormalities was based on the cancer therapy evaluation
program Common Toxicity Criteria version 2 (CTC), graded
from 0 to 4 [3] (e.g. grade 2 for asparate aminotransferase
(AST, U/l) and alanine aminotransferase (ALT, U/l) is >2.5–
5.0× upper limit of normal (ULN)). The following
laboratory parameters were available for analysis and were
felt to be most relevant for patient safety: leukopenia,
anemia, high creatinine, high AST, high ALT, low platelets,
low hemoglobin, high total bilirubin, hyper- or hyponatre-
mia, hyper- or hypokalemia.
2.3. Statistical analysis
Descriptive statistics were used in conjunction with 95%
confidence intervals calculated using a Poisson distribution
for the percent of patients with abnormalities. We used SAS
6.12 for Windows (SAS Institute Inc., Cary, NC) and STATA
6.0 (STATA Corporation, College Station, Texas, 1999).
3. Results
Of the 663 patients screened for entry into the randomized
trial of inhaled tobramycin, 520 CF subjects fulfilled
inclusion/exclusion criteria and received at least one dose
of study drug; 258 patients received tobramycin and 262
received placebo. Of the 520 CF subjects enrolled in the
study, 508 (98%) had complete baseline laboratory data
Table 2
Percent of CF patients in the inhaled tobramycin trial outside the laboratory
reference ranges at baseline
Laboratory parameter Below lower
limit (%)
Above upper
limit (%)
Total (%)
WBC count (109/l) 0.4 41.4 41.8
RBC count (106/μl) 0.2 1.6 1.8
Lymphocytes (%) 27.6 1.8 29.4
Platelet count (109/l) 3.0 23.4 26.4
Neutrophils (%) 2.0 28.2 30.2
Basophils (%) 0.0 2.6 2.6
Eosinophils (%) 0.0 3.6 3.6
Monocytes (%) 20.7 0.8 21.5
Hemoglobin (g/dl) 3.8 1.0 4.8
Hematocrit (%) 3.8 0.4 4.2
CO2 (mmol/l) 32.1 0.4 32.5
Creatinine (mg/dl) 24.0 0.8 24.8
Sodium (mEq/l) 0.8 9.2 10.0
Potassium (mEq/l) 0.0 7.1 7.1
Urea nitrogen (mg/dl) 9.1 3.5 12.6
Total bilirubin (mg/dl) 12.4 1.0 13.4
ALT (U/l) 2.2 16.1 18.3
AST (U/l) 0.8 11.8 12.6
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243 (93%) had data available from at least one post-baseline
visit to assess longitudinal variability in the laboratory
parameters. Table 1 describes the patient populations
included in our subsequent analyses.Fig. 1. Frequency histograms showing the distribution of baseline laboratory profil
white blood cell count (WBC) (units: 109/l); (c) asparate aminotransferase (AST)3.1. Baseline data
The laboratory parameters most often used to ensure
clinical stability at the time of enrollment in a clinical trial
include liver function tests of ASTand ALT, and the levels of
lymphocytes, neutrophils, hemoglobin, serum sodium and
serum creatinine. The eighteen laboratory parameters
available in the tobramycin trial were compared to the
reference ranges used by the study's central laboratory, and
the results are presented in Table 2. Even at a clinically stable
period of their disease, i.e. entrance into the study, 91% of
the 504 subjects had at least one laboratory measurement out
of the normal range with individual tests varying from 1.8%
to 41.8% outside the normal range across the 18 parameters.
A high percentage of CF patients have abnormal measure-
ments at baseline for several key laboratory parameters;
16.1% (95% CI: 12.8 to 20.0%) had an elevated AST above
the ULN at baseline, and 11.8% (95% CI: 9.0–15.2%) had an
elevated ALT above the ULN at baseline. Distribution of
laboratory abnormalities at baseline for neutrophil percent-
age, white blood cell count (WBC), AST and ALT are given
in Fig. 1.
Late phase clinical trials attempt to limit exclusion criteria
to enhance generalizability of the study results. In the inhaled
tobramycin trial, the only laboratory parameter used to
exclude subjects was an elevated creatinine (>2 mg/dl
[177 mmol/l]). However, in early phase clinical trials,es of trial subjects: (a) percent of neutrophils from complete blood count; (b)
in U/l; (d) alanine aminotransferase (ALT) in U/l.
Table 3
Percent of CF patients in the inhaled tobramycin trial excluded from clinical
trial participation using Common Exclusion Criteria
Laboratory parameter Exclusion criteria Patients excluded (%)
Hemoglobin <10 g/dl 0.2
Lymphocyte count <1.00×109/l 3.4
Neutrophil Count <1.50×109/l 0.6
Creatinine a >1.5×ULN 0.0
>2.0×ULN 0.0
AST a >2.0×ULN 2.4
>2.5×ULN 1.4
ALT a >2.0×ULN 3.5
>2.5×ULN 2.6
a For creatinine, ALT and AST, the exclusion criteria are based on the
upper limit of the laboratory-specific reference or “normal” range (ULN).
Fig. 2. Percent of subjects at baseline with specific laboratory tests greater
than or equal to grade 1 toxicity based on Common Toxicity Criteria (grades
1–3). White blood cell count (WBC), asparate aminotransferase (AST),
alanine aminotransferase (ALT).
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gives the proportion of CF patients in the tobramycin trial
that would have been excluded from the trial at baseline
using hypothetical cut-off laboratory values for eligibility
listed in the table. Although the percentages are small for this
study population who have already qualified for the clinical
trial, it may be of interest for future clinical trials to
investigate the cut-off laboratory values used for eligibility
determination to see if they significantly impact the number
of CF patients eligible for participation. Inclusion and
exclusion must be very carefully addressed for the limited
CF patient population prior to the start of a study to fully
understand the potential impact on enrollment with more
restrictive criteria.
Identification of adverse events resulting from changes in
baseline laboratory parameters is also a very important
function that needs to be performed during a clinical trial.
For this purpose, the laboratory measurements at study entry
and various time points during a clinical trial are used to
identify and grade the severity of adverse events. For this
study, the severity of the laboratory abnormalities at baseline
were graded using the CTC version 2; the CTC version 2 wasTable 4
Percent of CF patients in the inhaled tobramycin trial in each CTC severity
grade at baseline
Laboratory parameter Toxicity grade
1 (%) 2 (%) 3 (%)
WBC count (109/l) 0.4 0.0 0.0
Neutrophils (109/l) 0.4 0.2 0.4
Platelet count (109/l) 2.2 0.2 0.6
Hemoglobin (g/dl) 3.6 0.2 0.0
Creatinine (mg/dl) 0.8 0.0 0.0
Potassium (mEq/l)
Hypokalemia 0.0 0.0 0.0
Hyperkalemia 7.1 0.0 0.0
Sodium (mEq/l)
Hyponatremia 0.8 0.0 0.0
Hypernatremia 9.3 0.0 0.0
Total bilirubin (mg/dl) 0.8 0.2 0.0
ALT (U/l) 4.5 2.4 0.2
AST (U/l) 2.8 1.2 0.2the standard for toxicity grading in clinical trials in the
United States at the time of the inhaled tobramycin trial, and
although the criteria were not developed using a CF patient
population, they are based on clear markers of physiologic
abnormalities.
The percentages of tobramycin trial participants in each
severity grade at baseline for which CTC criteria were
available are shown in Table 4. Although 463 (91.1%, 95%
CI: 81.1–97.8%) of the trial participants had at least one
laboratory measurement outside the reference range at
baseline, a small percentage of these measurements areFig. 3. Percent of subjects whose laboratory values of AST, ALT,
hemoglobin and serum sodium changed from Common Toxicity Criteria
(CTC) grade 0 to 2 during the 24 week duration of the study in the placebo
arm of the study. Asparate aminotransferase (AST), alanine aminotransfer-
ase (ALT).
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guidelines (Fig. 2). Only the parameters of ALT, sodium, and
potassium show greater than 5% of patients with grade 1 or
higher toxicity at baseline with most of the abnormalities
being of grade 1, a level at which the clinical significance in
the CF population is likely limited (Fig. 2). 2.4% (95% CI:
1.2–4.1%) of CF subjects at baseline had an AST that would
have been graded a CTC grade 2 toxicity at baseline with
0.2% (95% CI: 0–1.0%) having a grade 3 toxicity. This
compares to a rate of 1.2% (95% CI: 0.4 –2.6%) of CF
subjects with ALT elevated to grade 2 toxicity and 0.2%
(95% CI: 0–1.0%) with grade 3 toxicity at baseline. Such
high background rates of CTC toxicity at baseline warrants
very careful interpretation of CTC toxicities that occur
during the actual trial. Thus, the identification and
interpretation of laboratory related adverse events are
challenging in early phase CF studies with either no placebo
group or a very small placebo group.
3.2. Longitudinal data
The variability of the laboratory measurements over time
was also examined for selected laboratory parameters using
the placebo patients in the inhaled tobramycin trial. Of the
243 placebo patients with measurements at baseline and at
least one subsequent visit, 242 (99.6%) had at least oneFig. 4. Longitudinal laboratory values for a random sample of 20 placebo
patients over the duration of the study for asparate aminotransferase (AST)
and alanine aminotransferase (ALT).laboratory parameter that changed from a “normal” to
“abnormal” classification at some point during the 24-week
study period. These shifts in classification of laboratory
abnormality are often described within the context of a
clinical trial in “shift tables,” showing the numbers of
subjects moving from normal to abnormal and visa-versa.
One hundred and fifty one (62.1%) had at least one
laboratory value change from grade 0 toxicity to grade 1
toxicity (Fig. 3). Twenty-eight (11.5%, 95% CI: 7.7–16.2%)
had at least one laboratory value change from grade 0
toxicity to grade 2 or higher toxicity. To further illustrate the
significant intra-patient variability of AST and ALT through
time during the study, we randomly selected 20 subjects and
plotted their laboratory values through time (Fig. 4). Our
analyses show that laboratory parameters are quite variable
over time in CF patients, and that it is very common in the
clinical trial setting for CF patients receiving placebo to
change from normal at baseline to abnormal during the study
for at least one laboratory parameter.
4. Discussion
This study is the first to our knowledge to detail the
laboratory values from CF patients both cross-sectionally at
baseline and longitudinally from the placebo arm of a large
randomized controlled trial. We have shown that baseline
laboratory values of otherwise clinically stable CF subjects
are often abnormal. Not only were they abnormal at study
initiation, but frequently went from normal (grade 0 CTC
toxicity) to abnormal (grade 1 or 2 toxicity) during the
conduct of the study. This study begins to describe the
natural history of CF patients in terms of their laboratory
parameter profiles for patients with similar disease severity,
and can be used to put into context data from clinical trials
with either no or very small placebo groups.
The laboratory tests that have been most thoroughly
discussed in the literature for CF patients are liver function
tests. Liver toxicity is one of the more important safety
concerns in clinical trials evaluating novel therapeutic
agents. Having high levels of baseline transaminase values
may confuse the interpretation of potential hepatotoxicity in
studies evaluating new therapies in CF. Several important
studies have assessed the natural history of liver disease in
CF and how this might relate to biochemical markers of liver
disease. Lindblad et al. followed 124 patients with annual
liver function tests from 1976 to 1993 [7]. More than 50% of
the patients had abnormal liver function tests in infancy that
normalized later in life. Approximately 25% of children
4 years of age or older had biochemical markers of liver
disease during the study period. Our study evaluated CF
subjects over a much shorter period of time with a much
higher frequency of laboratory assessment and similarly high
rates of abnormal tests. Liver function tests do appear to
fluctuate frequently. In a major study of liver disease in CF,
approximately 54% of the screened subjects with initial
abnormal liver function tests had normal follow-up studies
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very different population) mirrored these findings; liver
function tests fluctuated significantly over the 24-week
period of the study. In a similar study evaluating CF children
for liver disease, 63% of those children with an abnormal
liver ultrasound had abnormal liver function tests compared
with 21% of those children with normal architecture on liver
ultrasound [9].
Life threatening liver disease in CF is a rare event with
an incidence rate of 1.8% (95% CI: 1.3–2.4) (number of
cases per 100 person years) in spite of frequent episodes of
elevated liver function tests [10]. In addition, there is very
little correlation with biochemical markers of liver disease
and later development of liver disease; elevated LFTs on
one occasion were noted in 41% of those patients who
never developed liver disease. In another study, biochemical
abnormalities and/or clinical disease occurred in less than
half of those patients who had ultrasound evidence of liver
disease, and biochemical abnormalities at baseline were not
predictive ultrasound abnormalities [11]. This fact makes it
difficult to interpret the clinical significance of abnormal
liver function tests obtained during early clinical trials.
Understanding the frequency and degree to which each of
these liver function tests are abnormal is important to our
understanding of the natural history of this disease. Overall,
the general consensus in CF is that liver function tests do
vary considerably and may not directly reflect significant
liver pathology; rather, it may reflect intercurrent illness like
pulmonary exacerbation [12]. Thus, some of the abnormal
laboratories noted in this study might be due to pulmonary
exacerbations; we did not have data to permit this
assessment. In addition, laboratory abnormalities could be
due to concomitant medications used for routine care and to
treat exacerbations.
In contrast to liver function tests, limited data can be
found in the literature regarding other routine laboratory
tests that are performed on CF patients (platelet counts and
white blood cell counts). Smith et al. described the
reduction of white blood cell count with treatment of a
pulmonary exacerbation; mean white blood cell counts
decreased with therapy for pulmonary exacerbation but
were elevated at 11,676±4999 cells/μl roughly 2 weeks
after treatment with intravenous azlocillin and tobramycin
compared to 10,222±5309 cells/μl with azlocillin alone
[13]. Thus, despite being clinically improved, a significant
number of subjects had elevated WBCs 2 weeks after
treatment for a pulmonary exacerbation. This data differs
from other work which has shown a more dramatic response
of white blood cell count to treatment with intravenous
antibiotics [14,15]. While not directly comparable to our
current study given subjects had to fulfill criteria for
pulmonary exacerbation to qualify for enrollment, this data
suggests that elevation of white blood cell counts is
common in CF and may have a variable response to therapy.
Our study results could have potential ramifications in
the clinical trial setting. In the design and implementation ofa clinical trial, there are two main uses of laboratory testing:
defining eligibility (inclusion/exclusion) criteria, and devel-
oping a plan for identifying and monitoring adverse events.
Therefore, it should be recognized that the use of any
eligibility criteria that use laboratory-defined “normal” cut-
offs in the definition could lead to increased rates of clinical
trial exclusion that may have bearing on safety. Signifi-
cantly elevated laboratory values were uncommon; thus,
careful selection of inclusion and exclusion criteria may
best enhance study safety without significantly limited
access of CF patients to clinical trials. Such studies that
exclude patients based on common abnormalities may only
reflect a distinct subset of CF patients and not be
generalizable to the overall CF population. When monitor-
ing for adverse events, particularly in early phase trials,
understanding the frequency of abnormal tests in untreated
CF subjects may help interpret the laboratory related
adverse events that will inevitably occur in the trial.
The most important limitation of our study is that it is
derived from one clinical trial, the inhaled tobramycin trial,
which had distinct inclusion criteria. For the inhaled
tobramycin trial, the study population included patients
with mild to moderate CF related lung disease as defined by
spirometry (FEV1 % predicted >25% and <75%). In
addition, patients included were at least 6 years of age,
had a sputum that was culture positive for P. aeruginosa,
and had a serum creatinine less than 2 mg/dl. Thus, the
results of our analyses cannot be generalized to the CF
population as a whole. Since the patients included in this
study were considered stable at baseline, it is likely that we
have underestimated the true rate of abnormalities in the
general CF population. However, recent data suggests that
subjects participating in the inhaled tobramycin trial were
indeed representative of the general CF population who
fulfilled inclusion criteria [16]. The clinical trial population
may still differ from the general population in relation to
variables not addressed in inclusion and exclusion criteria
that would limit the generalizability of these results.
However, the findings of our study are most relevant to
those subjects participating in clinical trials. Our findings
are also based on a central laboratory, limiting site-specific
variability in laboratory results. Abnormal laboratory tests
that were noted in this analysis could have been due to
sample acquisition, specimen shipping and errors intro-
duced by the central laboratory. For studies that rely on
individual clinical site laboratories, variability is likely to be
greater and more challenging to interpret.
In summary, patients with CF frequently have laboratory
values outside the normal range with significant variability
of these values over time. Variability of liver function tests in
particular may complicate interpretation of safety data from
small phase I and II clinical trials. Interpretation of
laboratory related adverse events in the clinical trial setting
may be complicated by the underlying high rates of some
laboratory abnormalities in the CF population. For the design
of future studies, providing data on the longitudinal
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placebo arm subjects such as this one to Data Safety
Monitoring Boards may be useful so that they can anticipate
rates of laboratory related adverse events. Otherwise, high
levels of a grade 1 or higher toxicity could mistakenly be
attributed to the study drug when in reality no drug toxicity
occurred. This is particularly important for trials with rather
small placebo groups (i.e. dose escalation studies) or no
placebo group. Caution should still be maintained when
interpreting abnormal safety laboratories obtained during the
conduct of clinical trials in CF patients; hepatotoxicity
remains a potential significant safety concern for any novel
therapeutic agent. CF patients may be at increased risk of
hepatotoxicity given the high rate of underlying liver disease
related to CF.
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